Expanded Access to Tipifarnib
Study Details
Study Description
Brief Summary
This single-patient Expanded Access / Compassionate Use program is designed to provide access to single-agent tipifarnib for individual eligible adult patients with HRAS mutations or peripheral T Cell Lymphoma (PTCL) prior to approval by the local regulatory agency.
Importantly , expanded access for Tipifarnib is only available in the United States.
A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
Study Design
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Inclusion/Exclusion Criteria:
Suffer from HRAS-mutant carcinomas or peripheral T Cell Lymphoma (PTCL)
Adult, ages 18+
Have exhausted appropriate standard treatments without success and no comparable or satisfactory alternative treatment is available or exists to treat the disease or condition.
Are ineligible for participation in any ongoing clinical study of the investigational drug, which includes lack of access due to geographic limitations.
Meets any other pertinent medical criteria for access to the investigational drug, as established by the Kura Oncology clinical or medically responsible individual
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Kura Oncology, Inc.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Expanded Access to Tipifarnib